Greenwich LifeSciences (NASDAQ:GLSI) surged ahead in its clinical timeline on Tuesday, reporting a significant acceleration in patient recruitment for its pivotal Phase III breast cancer study.
The clinical-stage biopharmaceutical company announced that its FLAMINGO-01 trial—which evaluates the immunotherapy GLSI-100—has reached an annualized screening rate of over 800 patients per year.
This represents a 33% increase over previously reported metrics of 600 patients per year, a jump the company attributes to aggressive site activation across the U.S. and Europe throughout 2025.
Over the last six months, the company achieved its highest-ever volume, screening approximately 200 patients per quarter.
The trial targets the prevention of breast cancer recurrences in patients who have already undergone surgery, a high-stakes area of oncology that has earned the treatment a Fast Track designation from the U.S. Food and Drug Administration.
Chief Executive Officer Snehal Patel noted that the momentum is driven both by newly activated clinical sites and increasing "patient-driven" interest at existing locations.
The surge in enrollment capacity is a critical milestone for the small-cap biotech firm, as faster screening typically translates to shorter timelines for data readouts in late-stage trials.
The FLAMINGO-01 study remains the primary focus for Greenwich LifeSciences as it attempts to move GLSI-100 toward commercialization.
Investors have closely watched recruitment rates as a proxy for the company's operational efficiency in a competitive immunotherapy landscape.